Clinical Conversations, in a collaboration with CardioExchange, has interviewed two expert working clinicians on how best to use dabigatran — a drug poised to supplant warfarin in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
The wide ranging discussion with Drs. Elaine Hylek and Samuel Goldhaber includes sections on who should be on this new anticoagulant, management of the drug around surgical procedures, and promoting adherence, among others.
CardioExchange (h...
Clinical Conversations, in a collaboration with CardioExchange, has interviewed two expert working clinicians on how best to use dabigatran — a drug poised to supplant warfarin in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
The wide ranging discussion with Drs. Elaine Hylek and Samuel Goldhaber includes sections on who should be on this new anticoagulant, management of the drug around surgical procedures, and promoting adherence, among others.
CardioExchange (http://www.cardioexchange.org/) is an experiment in clinical community-building, sharing information from both Journal Watch and the New England Journal of Medicine. If you’re interested in matters of the heart you should really give it a look.
Related links for this podcast:
- The CardioExchange web site
- Guidelines from the ACC, AHA on using dabigatran, published in Circulation
- FDA approval of dabigatran
The post Podcast 115: Talking about the real-world use of dabigatran with Drs. Elaine Hylek and Samuel Goldhaber first appeared on Clinical Conversations.
View more